Skip to main content

Table 1 Epidemiological characteristic of PD patients

From: Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder

 

pRBD+

pRBD-

p

Patients number (n)

30

111

 

Age (yr)

68.33 ± 8.76

69.32 ± 9.75

0.618

PD duration (yr)

4.13 ± 4.22

4.65 ± 3.57

0.500

Gender, male, n (%)

18 (60.00)

56 (50.45)

0.655

Smoking, n (%)

4 (13.3)

11 (9.91)

0.525

Alcohol, n (%)

0

9 (8.11)

0.204

Coffee, n (%)

1 (3.33)

5 (4.50)

1.0

Levodopa dose equivalent (mg/day)

353.53 ± 236.10

339.10 ± 272.08

0.531

Levodopa dose (mg/day)

325.00 ± 205.84

285.15 ± 250.09

0.221

Levodopa years

2.59 ± 3.08

3.03 ± 3.31

0.577

Dopa agonist dose (mg/day)

38.23 ± 51.01

33.19 ± 45.12

0.931

Dopa agonist years

0.91 ± 1.52

4.41 ± 29.21

0.479

TCA(Deanxit), n (%)

1 (0.033)

1 (0.009)

>0.90

Trihexyphenidyl, n (%)

4 (0.133)

18 (0.162)

>0.90

SSRI, n (%)

2 (0.067)

3 (0.027)

>0.75

BNZ, n (%)

6 (0.2)

3 (0.027)

<0.005

  1. SSRI Selective Serotonin Reuptake Inhibitor
  2. BNZ Benzodiazepines, n: number
  3. The age, mean PD duration years, smoking, alcohol and coffee consumption rates, levodopa had no difference between two groups. However, the pRBD+ group had greater antidepressant and antihypnotic use